

DAFTAR PUSTAKA

- Allison, K.H., Hammond, M.E.H., Dowsett, M., McKernin, S.E., Carey, L.A., Fitzgibbons, P.L., Hayes, D.F., Lakhani, S.R., Chavez-MacGregor, M., Perlmutter, J., Perou, C.M., Regan, M.M., Rimm, D.L., Symmans, W.F., Torlakovic, E.E., Varella, L., Viale, G., Weisberg, T.F., McShane, L.M., Wolff, A.C., 2020. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. *J. Clin. Oncol.* 38: 1346–1366. doi:10.1200/JCO.19.02309
- Altman, N., Krzywinski, M., 2015. Points of Significance: Association, correlation and causation. *Nat. Methods* 12: 899–900. doi:10.1038/nmeth.3587
- Amens, J.N., Bahçecioglu, G., Zorlutuna, P., 2021. Immune System Effects on Breast Cancer. *Cell. Mol. Bioeng.* 14: 279–292. doi:10.1007/s12195-021-00679-8
- Andrews, J.L., Kim, A.C., Hens, J.R., 2012. Members of the cadherin superfamily provide cell-cell contact and communication in many different organ systems 1–10.
- Arnold, M., Morgan, E., Rungay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J.R., Cardoso, F., Siesling, S., Soerjomataram, I., 2022. Current and future burden of breast cancer: Global statistics for 2020 and 2040. *Breast* 66: 15–23. doi:10.1016/j.breast.2022.08.010
- Axel Buchner, Edgar Erdfelder, Franz Faul, Albert-Georg Lang, 2023. G*Power 3.1 manual: June 1, 2023.
- Bach, N., Winzer, R., Tolosa, E., Fiedler, W., Brauneck, F., 2023. The Clinical Significance of CD73 in Cancer. *Int. J. Mol. Sci.* 24: 1–21. doi:10.3390/ijms241411759
- Bai, Y.G., Gao, G.X., Zhang, H., Zhang, S., Liu, Y.H., Duan, X.N., Xu, L., 2020. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy. *Chin. Med. J. (Engl.)* 133: 552–560. doi:10.1097/CM9.0000000000000656
- Beatty, G and Gladney, W., 2015. Immune escape mechanisms as a guide for cancer immunotherapy. *Clin. Cancer Res.* 21: 687–692. doi:10.1158/1078-0432.CCR-14-1860
- Bertucci, F., Birnbaum, D., 2009. Distant metastasis: Not out of reach any more. *J. Biol.* 8: 8–12. doi:10.1186/jbiol1128
- Bowser, J.L., Broaddus, R.R., 2016. CD73s protection of epithelial integrity: Thinking beyond the barrier. *Tissue Barriers* 4: 1–11. doi:10.1080/21688370.2016.1224963
- Chan, H.L., Zhang, X.H.F., 2022. Node foretold: Cancer cells in lymph node rewire the immune system to enable further metastases. *Cancer Cell* 40: 812–814. doi:10.1016/j.ccell.2022.07.001
- Chatsirisupachai, K., Lagger, C., de Magalhães, J.P., 2022. Age-associated

- differences in the cancer molecular landscape. *Trends in Cancer* 8: 962–971. doi:10.1016/j.trecan.2022.06.007
- Cheishvili, D., Boureau, L., Szyf, M., 2015. DNA demethylation and invasive cancer: Implications for therapeutics. *Br. J. Pharmacol.* 172: 2705–2715. doi:10.1111/bph.12885
- Crooke, A., Martínez-Henández, J., Martínez-López, J., Cruz-Jentoft, A., Huete-Toral, F., Pintor, J., 2017. Low expression of CD39 and CD73 genes in centenarians compared with octogenarians. *Immun. Ageing* 14: 11–15. doi:10.1186/s12979-017-0094-3
- Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., Ghisini, R., Colleoni, M., Munzone, E., Veronesi, P., Zurrada, S., Nolè, F., Goldhirsch, A., 2009. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. *J. Clin. Oncol.* 27: 5693–5699. doi:10.1200/JCO.2009.22.0962
- Dewi, D.L., 2022. Karakterisasi Ekspresi dan Regulasi NLRC5 pada Kanker Payudara. Universitas Gadjah Mada.
- Dunnwald, L.K., Rossing, M.A., Li, C.I., 2007. Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. *Breast Cancer Res.* 9: 1–10. doi:10.1186/bcr1639
- El Bairi, K., Haynes, H.R., Blackley, E., Fineberg, S., Shear, J., Turner, S., de Freitas, J.R., Sur, D., Amendola, L.C., Gharib, M., Kallala, A., 2021. The tale of TILs in breast cancer: A report from The International Immunology Biomarker Working Group. *npj Breast Cancer* 7. doi:10.1038/s41523-021-00346-1
- Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., Ji, X., Liu, W., Huang, B., Luo, W., Liu, B., Lei, Y., Du, S., Vuppalapati, A., Luu, H.H., Haydon, R.C., He, T.C., Ren, G., 2018. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis.* 5: 77–106. doi:10.1016/j.gendis.2018.05.001
- Ferrand, A., Poleksic, J., Racine, E., 2022. Factors Influencing Physician Prognosis: A Scoping Review. *MDM Policy Pract.* 7: 1–16. doi:10.1177/23814683221145158
- Figenschau, S.L., Fismen, S., Fenton, K.A., Fenton, C., Mortensen, E.S., 2015. Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. *BMC Cancer* 15: 1–11. doi:10.1186/s12885-015-1116-1
- Giuliano, A.E., Edge, S.B., Hortobagyi, G.N., 2018. of the AJCC cancer staging manual: breast cancer. *Ann. Surg. Oncol.* 25: 1783–1785.
- Goff, S.L., Danforth, D.N., 2021. The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer. *Clin. Breast Cancer* 21: e63–e73. doi:10.1016/j.clbc.2020.06.011
- Goldberg, J.S., Cui, X., Shimada, K., McAllister, S., Tolaney, S., Waks, A., Jeselsohn, R., Guerriero, J., Agudo, J., Mittendorf, E., 2022. Abstract P1-04-13: Generation and validation of an estrogen receptor signaling (ERS) gene

panel that inversely correlates with antigen presentation and T cell infiltration and activity in hormone receptor positive (HR+) breast cancer. *Cancer Res.* 82: P1-04-13-P1-04-13. doi:10.1158/1538-7445.SABCS21-P1-04-13

- Goodman, L.A., Kruskal, W.H., 1954. Measures of Association for Cross Classifications Author (s): Leo A . Goodman and William H . Kruskal Source : Journal of the American Statistical Association , Vol . 49 , No . 268 (Dec ., 1954), pp . 732- Published by : American Statistical Associati. *J. Am. Stat. Assoc.* 49: 732–764.
- Guo, F.F., Cui, J.W., 2019. The role of tumor-infiltrating B cells in tumor immunity. *J. Oncol.* 2019. doi:10.1155/2019/2592419
- Huang, Y.K., Busuttil, R.A., Boussioutas, A., 2021. The role of innate immune cells in tumor invasion and metastasis. *Cancers (Basel)*. 13: 1–18. doi:10.3390/cancers13235885
- Jeong, Y.J., Oh, H.K., Choi, H.R., Park, S.H., 2020. Methylation of the nt5e gene is associated with poor prognostic factors in breast cancer. *Diagnostics* 10: 1–10. doi:10.3390/diagnostics10110939
- Ji, H., Hu, C., Yang, X., Liu, Y., Ji, G., Ge, S., Wang, X., Wang, M., 2023. Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. *Signal Transduct. Target. Ther.* 8. doi:10.1038/s41392-023-01576-4
- Jiang, T., Xu, X., Qiao, M., Li, X., Zhao, C., Zhou, F., Gao, G., Wu, F., Chen, X., Su, C., Ren, S., Zhai, C., Zhou, C., 2018. Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers. *BMC Cancer* 18: 1–10. doi:10.1186/s12885-018-4073-7
- Johnson, D.O., Moruf, B.Y., Popoola, S.O., Obafemi, W.K., Waheed, B.O., Kehinde, S.O., Oduwole, O.A., 2017. Awareness and Use of Surgical Checklist among Theatre Users at Ekiti State University Teaching Hospital, Ado-Ekiti, Nigeria. *Niger. J. Surg.* 23: 134–137. doi:10.4103/njs.NJS
- Kersh, A.E., Sasaki, M., Cooper, L.A., Kissick, H.T., Pollack, B.P., 2016. Understanding the impact of ErbB activating events and signal transduction on antigen processing and presentation: MHC expression as a model. *Front. Pharmacol.* 7: 1–18. doi:10.3389/fphar.2016.00327
- Koh, J., Kim, M.J., 2022. Erratum to: Introduction of a New Staging System of Breast Cancer for Radiologists: An Emphasis on the Prognostic Stage (Korean J Radiol 2019;20(1):69-82, 10.3348/kjr.2018.0231). *Korean J. Radiol.* 23: 570. doi:10.3348/kjr.2022.0246
- Kordaß, T., Osen, W., Eichmüller, S.B., 2018. Controlling the immune suppressor: Transcription factors and MicroRNAs regulating CD73/NT5E. *Front. Immunol.* 9: 1–8. doi:10.3389/fimmu.2018.00813
- Kotulová, J., Hajdúch, M., Džubák, P., 2021. Current adenosinergic therapies: What do cancer cells stand to gain and lose? *Int. J. Mol. Sci.* 22: 1–31. doi:10.3390/ijms222212569
- Kuhn, E., Gambini, D., Despini, L., Asnaghi, D., Runza, L., Ferrero, S., 2023. Updates on Lymphovascular Invasion in Breast Cancer. *Biomedicines* 11: 1–13. doi:10.3390/biomedicines11030968

- Laenkholm, A.V., Knoop, A., Ejlersen, B., Rudbeck, T., Jensen, M.B., Müller, S., Lykkesfeldt, A.E., Rasmussen, B.B., Nielsen, K.V., 2012. ESR1 gene status correlates with estrogen receptor protein levels measured by ligand binding assay and immunohistochemistry. *Mol. Oncol.* 6: 428–436. doi:10.1016/j.molonc.2012.04.003
- Lafont, V., Michaud, H.A., Bonnefoy, N., 2018. CD73: A new biomarker in triple-negative breast cancer. *Transl. Cancer Res.* 7: S594–S596. doi:10.21037/tcr.2018.05.22
- Lasek, W., 2022. Cancer immunoediting hypothesis : history , clinical implications and controversies 168–174.
- Lee, J., Park, H., Moon, S., Do, J.T., Hong, K., Choi, Y., 2021. Expression and regulation of CD73 during the estrous cycle in mouse uterus. *Int. J. Mol. Sci.* 22. doi:10.3390/ijms22179403
- Li, M., Zhou, C., 2021. Progesterone receptor gene serves as a prognostic biomarker associated with immune infiltration in gastric cancer: A bioinformatics analysis. *Transl. Cancer Res.* 10: 2663–2677. doi:10.21037/tcr-21-218
- Li, Y., Zhang, M., Zheng, X., 2018. High expression of NLRC5 is associated with prognosis of gastric cancer. *Open Med.* 13: 443–449. doi:10.1515/med-2018-0066
- Li, Z., Wei, H., Li, S., Wu, P., Mao, X., 2022. The Role of Progesterone Receptors in Breast Cancer. *Drug Des. Devel. Ther.* 16: 305–314. doi:10.2147/DDDT.S336643
- Liang, Y., Li, Q., He, D., Chen, Y., Li, J., 2021. Tumor size improves the accuracy of the prognostic prediction of T4a stage colon cancer. *Sci. Rep.* 11: 1–11. doi:10.1038/s41598-021-95828-4
- Lin, Z., Fang, D., 2013. The Roles of CD73 in Cancer. *Genes and Cancer* 4: 97–104. doi:10.1177/1947601912475079
- Livak, K.J., Schmittgen, T.D., 2001. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C(T)}$ Method. *Methods* 25: 402–408. doi:10.1006/meth.2001.1262
- Lo, N.C., Monteverde, M., Lee, S., Lattanzio, L., Vivenza, D., Comino, A., Syed, N., McHugh, A., Wang, H., Proby, C., Garrone, O., Merlano, M., Hatzimichael, E., Briasoulis, E., Gojis, O., Palmieri, C., Jordan, L., Quinlan, P., Thompson, A., Crook, T., 2012. NT5E CpG island methylation is a favourable breast cancer biomarker. *Br. J. Cancer* 107: 75–83. doi:10.1038/bjc.2012.212
- Lu, C., Liu, Y., Ali, N.M., Zhang, B., Cui, X., 2023. The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. *Front. Immunol.* 13: 1–14. doi:10.3389/fimmu.2022.1039260
- Lüönd, F., Tiede, S., Christofori, G., 2021. Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. *Br. J. Cancer* 125: 164–175. doi:10.1038/s41416-021-01328-7
- Lupia, M., Angiolini, F., Bertalot, G., Freddi, S., Sachsenmeier, K.F., Chisci, E., Kutryb-Zajac, B., Confalonieri, S., Smolenski, R.T., Giovannoni, R., Colombo, N., Bianchi, F., Cavallaro, U., 2018. CD73 Regulates Stemness

- and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells. *Stem Cell Reports* 10: 1412–1425. doi:10.1016/j.stemcr.2018.02.009
- Lv, L., Wei, Q., Wang, Z., Zhao, Y., Chen, N., Yi, Q., 2021. Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma. *Front. Bioeng. Biotechnol.* 9: 1–20. doi:10.3389/fbioe.2021.690186
- Mahdizadeh, M., Heydari, N., Shafiei, A., Akbari, H., Jafari, S.M., 2024. Adenosine receptors in breast cancer. *Mol. Biol. Rep.* 51. doi:10.1007/s11033-024-09382-z
- Makki, J., 2015. Diversity of breast carcinoma: Histological subtypes and clinical relevance. *Clin. Med. Insights Pathol.* 8: 23–31. doi:10.4137/CPath.s31563
- Maltoni, R., Ravaoli, S., Bronte, G., Mazza, M., Cerchione, C., Massa, I., Balzi, W., Cortesi, M., Zanoni, M., Bravaccini, S., 2022. Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? *Transl. Oncol.* 15: 101300. doi:10.1016/j.tranon.2021.101300
- Mills, J.H., Alabanza, L.M., Mahamed, D.A., Bynoe, M.S., 2012. Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis. *J. Neuroinflammation* 9: 1–12. doi:10.1186/1742-2094-9-193
- Munhoz, R.R., Postow, M.A., 2016. Recent advances in understanding antitumor immunity. *F1000Research* 5: 2545. doi:10.12688/f1000research.9356.1
- Nascimento, R.G. do, Otoni, K.M., 2020. Histological and molecular classification of breast cancer: what do we know? *Mastology* 30: 1–8. doi:10.29289/25945394202020200024
- Ndzie Noah, M.L., Adzika, G.K., Mprah, R., Adekunle, A.O., Koda, S., Adu-Amankwaah, J., Xu, Y., Kanwore, K., Wowui, P.I., Sun, H., 2023. Estrogen downregulates CD73/adenosine axis hyperactivity via adaptive modulation PI3K/Akt signaling to prevent myocarditis and arrhythmias during chronic catecholamines stress. *Cell Commun. Signal.* 21: 1–11. doi:10.1186/s12964-023-01052-0
- Pedroza, D.A., Subramani, R., Lakshmanaswamy, R., 2020. Classical and non-classical progesterone signaling in breast cancers. *Cancers (Basel)*. 12: 1–16. doi:10.3390/cancers12092440
- Pinhel, I., Hills, M., Drury, S., Salter, J., Sumo, G., A'Hern, R., Bliss, J.M., Sestak, I., Cuzick, J., Barrett-Lee, Peter, Harris, A., Dowsett, M., Bliss, M., Johnson, L., Lawrence, D., Price, D., Peto, J., Yarnold, J., Barrett-Lee, P., Brunt, A.M., Dodwell, D., Earl, H., Fernando, I., Foster, L., George, W.D., Harnett, A.M., Perren, T., Poole, C., Raina, V., Robinson, A., 2012. ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer. *Breast Cancer Res.* 14. doi:10.1186/bcr3145
- Rashid, O.M., Takabe, K., 2012. Sentinel lymph node biopsy for breast cancer: our technique and future directions in lymph node staging. *J. Nucl. Med. Radiat. Ther.* 2012.
- Reticker-Flynn, N.E., Zhang, W., Belk, J.A., Basto, P.A., Escalante, N.K., Pilarowski, G.O.W., Bejnood, A., Martins, M.M., Kenkel, J.A., Linde, I.L., Bagchi, S., Yuan, R., Chang, S., Spitzer, M.H., Carmi, Y., Cheng, J.,

- Tolentino, L.L., Choi, O., Wu, N., Kong, C.S., Gentles, A.J., Sunwoo, J.B., Satpathy, A.T., Plevritis, S.K., Engleman, E.G., 2022. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. *Cell* 185: 1924–1942.e23. doi:10.1016/j.cell.2022.04.019
- Rezo, A., Dahlstrom, J., Shadbolt, B., Rodins, K., Zhang, Y., Davis, A.J., 2011. Tumor size and survival in multicentric and multifocal breast cancer. *Breast* 20: 259–263. doi:10.1016/j.breast.2011.01.005
- Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F.L., Penault-Llorca, F., Perez, E.A., Thompson, E.A., Symmans, W.F., Richardson, A.L., Brock, J., Criscitiello, C., Bailey, H., Ignatiadis, M., Floris, G., Sparano, J., Kos, Z., Nielsen, T., Rimm, D.L., Allison, K.H., Reis-Filho, J.S., Loibl, S., Sotiriou, C., Viale, G., Badve, S., Adams, S., Willard-Gallo, K., Loi, S., 2015. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILS Working Group 2014. *Ann. Oncol.* 26: 259–271. doi:10.1093/annonc/mdu450
- Shukla, A., Cloutier, M., Santharam, M.A., Ramanathan, S., Ilangumaran, S., 2021. The mhc class-i transactivator nlrc5: Implications to cancer immunology and potential applications to cancer immunotherapy. *Int. J. Mol. Sci.* 22: 1–36. doi:10.3390/ijms22041964
- Tamura, D., Hiraga, T., Myoui, A., Yoshikawa, H., Yoneda, T., 2008. Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. *Int. J. Oncol.* 33: 17–24. doi:10.3892/ijo.33.1.17
- Tang, F., Xu, Y., Zhao, B., 2020. NLRC5: new cancer buster? *Mol. Biol. Rep.* 47: 2265–2277. doi:10.1007/s11033-020-05253-5
- van Dooijeweert, C., van Diest, P.J., Ellis, I.O., 2022. Grading of invasive breast carcinoma: the way forward. *Virchows Arch.* 480: 33–43. doi:10.1007/s00428-021-03141-2
- Wang, H., Lee, S., Lo Nigro, C., Lattanzio, L., Merlano, M., Monteverde, M., Matin, R., Purdie, K., Mladkova, N., Bergamaschi, D., Harwood, C., Syed, N., Szlosarek, P., Briasoulis, E., McHugh, A., Thompson, A., Evans, A., Leigh, I., Fleming, C., Inman, G.J., Hatzimichael, E., Proby, C., Crook, T., 2012. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. *Br. J. Cancer* 106: 1446–1452. doi:10.1038/bjc.2012.95
- Wang, Y., Acs, B., Robertson, S., Liu, B., Solorzano, L., Wählby, C., Hartman, J., Rantalainen, M., 2022. Improved breast cancer histological grading using deep learning. *Ann. Oncol.* 33: 89–98. doi:10.1016/j.annonc.2021.09.007
- WHO, 2020a. The Global Cancer Observatory - All cancers. *Int. Agency Res. Cancer - WHO* 419: 199–200.
- WHO, 2020b. Cancer in Indonesia. *Int. Agency Res. Cancer - WHO* 419.
- Widodo, I., Dwianingsih, E.K., Anwar, S.L., Triningsih, F.E., Utoro, T., Aryandono, T., Soeripto, 2017. Prognostic value of clinicopathological factors for Indonesian breast carcinomas of different molecular subtypes. *Asian Pacific J. Cancer Prev.* 18: 1251–1256.

doi:10.22034/APJCP.2017.18.5.1251

- Widodo, I., Dwianingsih, E.K., Aryandono, T., Soeripto, 2019. Clinicopathological characteristic and prognostic significance of Indonesian triple negative breast cancer. *Indones. Biomed. J.* 11: 286–292. doi:10.18585/inabj.v11i3.831
- Widodo, I., Dwianingsih, E.K., Triningsih, E., Utoro, T., Soeripto, 2014. Clinicopathological features of Indonesian breast cancers with different molecular subtypes. *Asian Pacific J. Cancer Prev.* 15: 6109–6113. doi:10.7314/APJCP.2014.15.15.6109
- Ye, F., Dewanjee, S., Li, Y., Jha, N.K., Chen, Z.S., Kumar, A., Vishakha, Behl, T., Jha, S.K., Tang, H., 2023. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. *Mol. Cancer* 22: 1–40. doi:10.1186/s12943-023-01805-y
- Yegutkin, G.G., Auvinen, K., Rantakari, P., Hollmén, M., Karikoski, M., Grénman, R., Elima, K., Jalkanen, S., Salmi, M., 2015. Ecto-5'-nucleotidase/CD73 enhances endothelial barrier function and sprouting in blood but not lymphatic vasculature. *Eur. J. Immunol.* 45: 562–573. doi:10.1002/eji.201444856
- Yoshihama, S., Roszik, J., Downs, I., Meissner, T.B., Vijayan, S., Chapuy, B., Sidiq, T., Shipp, M.A., Lizee, G.A., Kobayashi, K.S., 2016. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. *Proc. Natl. Acad. Sci. U. S. A.* 113: 5999–6004. doi:10.1073/pnas.1602069113
- Yoshihama, S., Vijayan, S., Sidiq, T., Kobayashi, K.S., 2017. NLRC5/CITA: a key player in cancer immune surveillance. *Trends in cancer* 3: 28–38.
- Zeng, Q., Chen, X., Ning, C., Zhu, Q., Yao, Y., Zhao, Y., Luan, F., 2018. Methylation of the genes ROD1, NLRC5, and HKR1 is associated with aging in Hainan centenarians. *BMC Med. Genomics* 11: 1–11. doi:10.1186/s12920-018-0334-1
- Zhang, Y., Guan, X.Y., Jiang, P., 2020. Cytokine and Chemokine Signals of T-Cell Exclusion in Tumors. *Front. Immunol.* 11: 1–20. doi:10.3389/fimmu.2020.594609
- Zhao, M.Z., Sun, Y., Jiang, X.F., Liu, L., Sun, L.X., 2019. Promotion on NLRC5 upregulating MHC-I expression by IFN- γ in MHC-I-deficient breast cancer cells. *Immunol. Res.* 67: 497–504. doi:10.1007/s12026-019-09111-w
- Zhi, X., Wang, Y., Yu, Jerry, Yu, Jiangang, Zhang, L., Yin, L., Zhou, P., 2012. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer. *IUBMB Life* 64: 911–920. doi:10.1002/iub.1086
- Zhi, X., Wang, Y., Zhou, X., Yu, J., Jian, R., Tang, S., Yin, L., Zhou, P., 2010. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. *Cancer Sci.* 101: 2561–2569. doi:10.1111/j.1349-7006.2010.01733.x
- Zhou, P., Yang, J., 2012. NT5E (5'-nucleotidase, ecto (CD73)). *Atlas Genet. Cytogenet. Oncol. Haematol.* 16: 655–657. doi:10.4267/2042/47536